AR090293A1 - Inhibidores de quinasa a base de arileter - Google Patents
Inhibidores de quinasa a base de arileterInfo
- Publication number
- AR090293A1 AR090293A1 ARP130100766A ARP130100766A AR090293A1 AR 090293 A1 AR090293 A1 AR 090293A1 AR P130100766 A ARP130100766 A AR P130100766A AR P130100766 A ARP130100766 A AR P130100766A AR 090293 A1 AR090293 A1 AR 090293A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- halo
- alkoxy
- hydrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos que pueden inhibir la AAK1 (quinasa asociada con el adaptador 1), composiciones que comprenden tales compuestos y métodos para inhibir la AAK1. Útil para tratar esquizofrenia, Parkinson, dolor neuropático, trastorno bipolar y Alzheimer. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o una de sus sales farmacéuticamente aceptables, en donde: R¹ y R² están seleccionados, de modo independiente, de hidrógeno, cicloalquilo C₃₋₆ y alquilo C₁₋₃, en donde el alquilo C₁₋₃ está opcionalmente sustituido con uno, dos o tres grupos seleccionados, de modo independiente, de alcoxi C₁₋₃, alquil C₁₋₃-amino, amino, ciano, dialquil C₁₋₃-amino, halo e hidroxi; o R¹ y R² juntos son oxo; o R¹ y R², junto con el átomo de carbono al que están unidos, forman un anillo oxetano; R³ es alquil C₁₋₃-Y o alquilo C₂₋₈, en donde el alquilo C₂₋₈ está opcionalmente sustituido con uno, dos, tres o cuatro grupos seleccionados, de modo independiente, de alcoxi C₁₋₃, alquil C₁₋₃-amino, alcoxi C₁₋₃-alquil C₂₋₃-amino, amino, arilo, halo, haloalquil C₁₋₃-amino, haloalquil C₁₋₃-carbonilamino, hidroxi, -NRˣRʸ y cicloalquilo C₃₋₈, en donde el cicloalquilo está también opcionalmente sustituido con uno, dos o tres grupos seleccionados, de modo independiente, de alcoxi C₁₋₃, alquilo C₁₋₃, alquil C₁₋₃-amino, alcoxi C₁₋₃-alquil C₂₋₃-amino, amino, arilo, arilalquilo C₁₋₃, halo, haloalquilo C₁₋₃, haloalquil C₁₋₃-amino e hidroxi; R⁴ está seleccionado de hidrógeno, alcoxi C₁₋₃, alcoxi C₁₋₃-carbonilamino, alquilo C₁₋₃, alquil C₁₋₃-amino, alquil C₁₋₃-carbonilamino, amino, arilamino, arilcarbonilamino, cicloalquil C₃₋₆-amino, cicloalquil C₃₋₆-carbonilamino, cicloalquil C₃₋₆-oxi, halo, haloalcoxi C₁₋₃, haloalquil C₂₋₃amino, haloalquil C₂₋₃carbonilamino e hidroxi; R⁵ está seleccionado de hidrógeno, alquilo C₁₋₃, ciano, cicloalquilo C₃ y halo; R⁶ está seleccionado de hidrógeno, alquilo C₁₋₃, alquil C₁₋₃-carbonilamino, amino; R⁷ está seleccionado de hidrógeno, alcoxi C₁₋₃, alquilo C₁₋₃, ciano, -CH₂OH, -CH₂OCH₃, CH(CH₃)OH, C(CH₃)₂OH, halo y haloalquilo C₁₋₃; R⁸ está seleccionado de hidrógeno, alcoxi C₁₋₃, ciano y halo; Rˣ y Rʸ, junto con el átomo de nitrógeno al que están unidos, forman un anillo de tres a seis miembros; e Y está seleccionado del grupo de fórmulas (2); en donde R⁹ está seleccionado de hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ y alquil C₁₋₆-carbonilo; n es 0, 1, 2 ó 3; cada R¹⁰ está seleccionado, de modo independiente, de hidrógeno, alquilo C₁₋₆, arilo, arilalquilo C₁₋₃, cicloalquilo C₃₋₆, halo y haloalquilo C₁₋₃; y cada R¹¹ está seleccionado, de modo independiente, de hidrógeno, alcoxi C₁₋₃ e hidroxi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608737P | 2012-03-09 | 2012-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090293A1 true AR090293A1 (es) | 2014-11-05 |
Family
ID=47892007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100766A AR090293A1 (es) | 2012-03-09 | 2013-03-11 | Inhibidores de quinasa a base de arileter |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8703953B2 (es) |
| EP (1) | EP2822952B1 (es) |
| JP (1) | JP2015510881A (es) |
| CN (1) | CN104144932A (es) |
| AR (1) | AR090293A1 (es) |
| CA (1) | CA2866671A1 (es) |
| EA (1) | EA201491647A1 (es) |
| MX (1) | MX2014010684A (es) |
| TW (1) | TW201341387A (es) |
| UY (1) | UY34666A (es) |
| WO (1) | WO2013134036A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| EP2958924B1 (en) | 2013-02-22 | 2016-12-28 | Bristol-Myers Squibb Company | 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1) |
| WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物 |
| WO2015006100A1 (en) | 2013-07-08 | 2015-01-15 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
| JP6243539B2 (ja) * | 2013-09-11 | 2017-12-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アリールエーテルをベースとするキナーゼ阻害剤 |
| CN105979950A (zh) | 2013-10-11 | 2016-09-28 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| US20160333006A1 (en) * | 2014-01-29 | 2016-11-17 | Bristol-Myers Squibb Company | Aryl lacta kinase inhibitors |
| CN106132951B (zh) * | 2014-01-31 | 2019-02-12 | 百时美施贵宝公司 | 基于喹啉的激酶抑制剂 |
| SG11201608195QA (en) | 2014-04-02 | 2016-10-28 | Bristol Myers Squibb Co | Biaryl kinase inhibitors |
| EP3292124B1 (en) * | 2015-04-10 | 2019-05-22 | Bristol-Myers Squibb Company | 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors |
| WO2016191245A1 (en) * | 2015-05-22 | 2016-12-01 | Dow Agrosciences Llc | Recovery and/or reuse of palladium catalyst after a suzuki coupling |
| US10544120B2 (en) | 2015-10-01 | 2020-01-28 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
| WO2017059080A1 (en) * | 2015-10-01 | 2017-04-06 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
| TWI673271B (zh) | 2016-12-15 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | 製備btk抑制劑之方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0672031T3 (da) | 1992-12-02 | 2003-06-10 | Pfizer | Catecholdiethere som selektive PDE IV-inhibitorer |
| US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| US20070060606A1 (en) * | 1999-10-07 | 2007-03-15 | Robertson Harold A | Compounds and methods for modulating phosphodiesterase 10A |
| DE60319686T2 (de) | 2002-04-05 | 2009-04-16 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Cyanamide als reversible hemmer von cystein proteasen |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| WO2004072018A1 (ja) | 2003-02-12 | 2004-08-26 | Takeda Pharmaceutical Company Limited | アミン誘導体 |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| CA2570694A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| CN100494167C (zh) | 2005-08-02 | 2009-06-03 | 天津大学 | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 |
| JP2007217408A (ja) | 2006-01-19 | 2007-08-30 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| EP2007756B1 (en) | 2006-04-07 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| WO2008022155A2 (en) | 2006-08-14 | 2008-02-21 | Wyeth | Methods of identifying agents for treating neurological disorders |
| WO2008153814A2 (en) * | 2007-05-29 | 2008-12-18 | President And Fellows Of Harvard College | Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof |
| DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
-
2013
- 2013-02-26 US US13/777,144 patent/US8703953B2/en active Active
- 2013-02-28 EA EA201491647A patent/EA201491647A1/ru unknown
- 2013-02-28 CN CN201380012323.6A patent/CN104144932A/zh active Pending
- 2013-02-28 EP EP13710203.4A patent/EP2822952B1/en active Active
- 2013-02-28 JP JP2014560950A patent/JP2015510881A/ja not_active Withdrawn
- 2013-02-28 WO PCT/US2013/028230 patent/WO2013134036A1/en active Application Filing
- 2013-02-28 CA CA2866671A patent/CA2866671A1/en not_active Abandoned
- 2013-02-28 MX MX2014010684A patent/MX2014010684A/es unknown
- 2013-03-08 UY UY0001034666A patent/UY34666A/es unknown
- 2013-03-08 TW TW102108352A patent/TW201341387A/zh unknown
- 2013-03-11 AR ARP130100766A patent/AR090293A1/es unknown
-
2014
- 2014-02-24 US US14/188,141 patent/US8969564B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104144932A (zh) | 2014-11-12 |
| US20140179725A1 (en) | 2014-06-26 |
| MX2014010684A (es) | 2014-10-17 |
| CA2866671A1 (en) | 2013-09-12 |
| US8969564B2 (en) | 2015-03-03 |
| JP2015510881A (ja) | 2015-04-13 |
| WO2013134036A1 (en) | 2013-09-12 |
| TW201341387A (zh) | 2013-10-16 |
| UY34666A (es) | 2013-09-30 |
| EP2822952B1 (en) | 2016-04-06 |
| EP2822952A1 (en) | 2015-01-14 |
| US8703953B2 (en) | 2014-04-22 |
| EA201491647A1 (ru) | 2014-12-30 |
| US20130237555A1 (en) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090293A1 (es) | Inhibidores de quinasa a base de arileter | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR105103A1 (es) | Derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR105101A1 (es) | Derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR062011A1 (es) | Derivados de diazol y sus composiciones como inhibidores de itpkb | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR085748A1 (es) | Piridinonas biciclicas | |
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
| AR085602A1 (es) | Inhibidores de quinasas, composiciones farmaceuticas y su aplicacion en el tratamiento de canceres y trastornos autoinmunes | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR100776A1 (es) | Compuestos herbicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |